Fitness7 months ago
Darolutamide Increases OS, Delays Progression From mHSPC to mCRPC
Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) and docetaxel improved overall survival and delay time to progression to metastatic castration-resistant disease when compared with placebo plus...
